PMID- 32679712
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210219
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 21
IP  - 14
DP  - 2020 Jul 15
TI  - Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide 
      Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary 
      Hypercholesterolemia.
LID - 10.3390/ijms21144983 [doi]
LID - 4983
AB  - Platelet hyperactivation is involved in the established prothrombotic condition 
      of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM) and familial 
      hypercholesterolemia (HC), justifying the therapy with aspirin, a suppressor of 
      thromboxane synthesis through the irreversible inhibition of cyclooxygenase-1 
      (COX-1), to prevent cardiovascular diseases. However, some patients on aspirin 
      show a higher than expected platelet reactivity due, at least in part, to a 
      pro-oxidant milieu. The aim of this study was to investigate platelet reactivity 
      in T2DM (n = 103) or HC (n = 61) patients (aspirin, 100 mg/day) and its 
      correlation with biomarkers of redox function including the superoxide anion 
      scavenger superoxide dismutase (SOD) and the in vivo marker of oxidative stress 
      urinary 8-iso-prostaglandin F(2alpha). As results, in T2DM and HC subjects the 
      prevalence of high on-aspirin platelet reactivity was comparable when both 
      non-COX-1-dependent and COX-1-dependent assays were performed, and platelet 
      reactivity is associated with a lower SOD activity that in a stepwise linear 
      regression appears as the only predictor of platelet reactivity. To conclude, in 
      T2DM and HC, similarly, the impairment of redox equilibrium associated with a 
      decrease of SOD activity could contribute to a suboptimal response to aspirin.
FAU - Barale, Cristina
AU  - Barale C
AD  - Department of Clinical and Biological Sciences of Turin University, 10043 
      Orbassano, Turin, Italy.
FAU - Cavalot, Franco
AU  - Cavalot F
AD  - Metabolic Disease and Diabetes Unit, San Luigi Gonzaga Hospital, 10043 Orbassano, 
      Turin, Italy.
FAU - Frascaroli, Chiara
AU  - Frascaroli C
AD  - Metabolic Disease and Diabetes Unit, San Luigi Gonzaga Hospital, 10043 Orbassano, 
      Turin, Italy.
FAU - Bonomo, Katia
AU  - Bonomo K
AD  - Metabolic Disease and Diabetes Unit, San Luigi Gonzaga Hospital, 10043 Orbassano, 
      Turin, Italy.
FAU - Morotti, Alessandro
AU  - Morotti A
AUID- ORCID: 0000-0002-8407-2903
AD  - Department of Clinical and Biological Sciences of Turin University, 10043 
      Orbassano, Turin, Italy.
FAU - Guerrasio, Angelo
AU  - Guerrasio A
AD  - Department of Clinical and Biological Sciences of Turin University, 10043 
      Orbassano, Turin, Italy.
FAU - Russo, Isabella
AU  - Russo I
AUID- ORCID: 0000-0002-2921-1763
AD  - Department of Clinical and Biological Sciences of Turin University, 10043 
      Orbassano, Turin, Italy.
LA  - eng
PT  - Journal Article
DEP - 20200715
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Thromboxanes)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aged
MH  - Aspirin/administration & dosage/*therapeutic use
MH  - Blood Platelets/drug effects
MH  - Cyclooxygenase Inhibitors/administration & dosage/therapeutic use
MH  - Diabetes Mellitus, Type 2/*complications/metabolism
MH  - Female
MH  - Humans
MH  - Hypercholesterolemia/*complications/metabolism
MH  - Male
MH  - Middle Aged
MH  - Oxidative Stress/drug effects
MH  - Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use
MH  - Superoxide Dismutase/*metabolism
MH  - Thrombosis/etiology/metabolism/*prevention & control
MH  - Thromboxanes/metabolism
PMC - PMC7404318
OTO - NOTNLM
OT  - aspirin
OT  - oxidative stress
OT  - platelet function analyzer-100
OT  - platelets
OT  - superoxide dismutase
OT  - thromboxane
COIS- The authors declare no conflict of interest.
EDAT- 2020/07/19 06:00
MHDA- 2021/02/20 06:00
PMCR- 2020/07/01
CRDT- 2020/07/19 06:00
PHST- 2020/06/05 00:00 [received]
PHST- 2020/07/11 00:00 [revised]
PHST- 2020/07/13 00:00 [accepted]
PHST- 2020/07/19 06:00 [entrez]
PHST- 2020/07/19 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/07/01 00:00 [pmc-release]
AID - ijms21144983 [pii]
AID - ijms-21-04983 [pii]
AID - 10.3390/ijms21144983 [doi]
PST - epublish
SO  - Int J Mol Sci. 2020 Jul 15;21(14):4983. doi: 10.3390/ijms21144983.